<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="world. Some drugs such as lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="have been recommended for COVID-19 treatment by some researchers,"/>
 <result pre="(MD) simulation indicates that binding of the combination therapy of" exact="simeprevir" post="and the candidate studied compounds to the receptors was"/>
 <result pre="a combination therapy along with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="for disrupting the stability of SARS-CoV2 receptor proteins to"/>
 <result pre="effective drug against SARS-CoV-2, but some previous studies reported that" exact="chloroquine" post="and remdesivir inhibited SARS-CoV-2 and the possibility of using"/>
 <result pre="and its derivatives along with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="for disrupting the stability of SARS-CoV-2 receptor proteins to"/>
 <result pre="performed to study the binding of the combination therapy of" exact="simeprevir" post="and the candidate studied compounds to the receptors and"/>
 <result pre="before docking. The structures of lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="were obtained from the PubChem database. The structural optimization"/>
 <result pre="highest binding complexes obtained from the molecular docking study of" exact="simeprevir" post="+ compound 7–6LU7, simeprevir + compound 19–6LU7, simeprevir +"/>
 <result pre="from the molecular docking study of simeprevir + compound 7–6LU7," exact="simeprevir" post="+ compound 19–6LU7, simeprevir + compound 7–6VYP, and simeprevir"/>
 <result pre="study of simeprevir + compound 7–6LU7, simeprevir + compound 19–6LU7," exact="simeprevir" post="+ compound 7–6VYP, and simeprevir + compound 7–6VYP complexes"/>
 <result pre="7–6LU7, simeprevir + compound 19–6LU7, simeprevir + compound 7–6VYP, and" exact="simeprevir" post="+ compound 7–6VYP complexes were prepared for MD simulation"/>
 <result pre="drugs. Hence, individual drugs like lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="may not be able to disrupt the stability of"/>
 <result pre="to all the chemical drugs lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="as shown in Table 2 in the state of"/>
 <result pre="to all the chemical drugs lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="as shown in Table 2 in the state of"/>
 <result pre="in molecular docking together with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="for disrupting the stability of SARS-CoV-2 main protease and"/>
 <result pre="in combination therapy along with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="drugs which are actually used in the treatment of"/>
 <result pre="than those of the drugs lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="against 6VYB and 6LU7. These results of molecular docking"/>
 <result pre="potent antiviral molecules along with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="or other antiviral conventional drugs for disruption of the"/>
 <result pre="and 12 show the schematic presentation of combination therapy of" exact="simeprevir" post="with compounds 7, 10, and 19 suppressing the activity"/>
 <result pre="respectively. Fig. 11 Schematic presentation for the combination therapy of" exact="simeprevir" post="with compounds 7, 10, and 19 suppressing the activity"/>
 <result pre="cycle Fig. 12 Schematic presentation for the combination therapy of" exact="simeprevir" post="with compounds 7, 10, and 19 suppressing the activity"/>
 <result pre="simulations were carried out for the highest binding energy of" exact="simeprevir" post="with compounds 7 and 19 inside 6VYB and 6LU7"/>
 <result pre="solvated a 6LU7 and b 6VYB receptors in complex with" exact="simeprevir" post="+ compound 7 during molecular dynamics simulations at 10"/>
 <result pre="yellow atoms represented compound 7 in the bottom view and" exact="simeprevir" post="in the top view, the red and white colors"/>
 <result pre="the studied systems were 1.15 ± 0.04, 1.74 ± 0.08, 1.53 ± 0.03, and 1.30 ± 0.12 for" exact="simeprevir" post="+ compound 7–6LU7, simeprevir + compound 19–6LU7, simeprevir +"/>
 <result pre="1.15 ± 0.04, 1.74 ± 0.08, 1.53 ± 0.03, and 1.30 ± 0.12 for simeprevir + compound 7–6LU7," exact="simeprevir" post="+ compound 19–6LU7, simeprevir + compound 7–6VYP, and simeprevir"/>
 <result pre="1.30 ± 0.12 for simeprevir + compound 7–6LU7, simeprevir + compound 19–6LU7," exact="simeprevir" post="+ compound 7–6VYP, and simeprevir + compound 7–6VYP complexes,"/>
 <result pre="7–6LU7, simeprevir + compound 19–6LU7, simeprevir + compound 7–6VYP, and" exact="simeprevir" post="+ compound 7–6VYP complexes, respectively. Fig. 14 Plot of"/>
 <result pre="time for solvated 6LU7 and 6VYB receptors in complex with" exact="simeprevir" post="+ compounds 7 and 19 during molecular dynamics simulations"/>
 <result pre="of the complex indicates its stability with combination therapy of" exact="simeprevir" post="and the two candidate compounds and provided a suitable"/>
 <result pre="of solvated 6LU7 and 6VYB receptors, receptively, in complex with" exact="simeprevir" post="+ compounds 7 and 19 during 10 ns molecular"/>
 <result pre="for the complex indicates that binding of combination therapy of" exact="simeprevir" post="and the two candidate compounds to the receptors was"/>
 <result pre="RMSF values were 0.55 ± 0.07, 0.69 ± 0.09, and 0.87 ± 0.07 Å for 6LU7," exact="simeprevir" post="+ compound 7–6LU7, and simeprevir + compound 19–6LU7 complexes,"/>
 <result pre="and 0.87 ± 0.07 Å for 6LU7, simeprevir + compound 7–6LU7, and" exact="simeprevir" post="+ compound 19–6LU7 complexes, respectively, and 0.35 ± 0.03, 0.41 ± 0.07, and"/>
 <result pre="complexes, respectively, and 0.35 ± 0.03, 0.41 ± 0.07, and 0.58 ± 0.05 Å for 6VYB," exact="simeprevir" post="+ compound 7–6VYB, and simeprevir + compound 19–6VYB complexes,"/>
 <result pre="and 0.58 ± 0.05 Å for 6VYB, simeprevir + compound 7–6VYB, and" exact="simeprevir" post="+ compound 19–6VYB complexes, respectively. Fig. 15 The root"/>
 <result pre="(RMSF) values of 6LU7 protease alone and in complex with" exact="simeprevir" post="+ compounds 7 and 19 were plotted against residue"/>
 <result pre="(RMSF) values of 6VYB receptor alone and in complex with" exact="simeprevir" post="+ compounds 7 and 19 were plotted against residue"/>
 <result pre="in molecular docking along with lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="for disrupting the stability of SARS-CoV-2 main protease and"/>
 <result pre="stability of the combination therapy between the studied compounds and" exact="simeprevir" post="inside 6LU7 and 6VYB receptors. Hence, the combination of"/>
 <result pre="6VYB receptors. Hence, the combination of the studied compounds and" exact="simeprevir" post="is highly effective against SARS-CoV-2 protease, and these drugs"/>
 <result pre="Finally, the antiviral activity of lopinavir, simeprevir, hydroxychloroquine, chloroquine, and" exact="amprenavir" post="could be increased against SARS-CoV-2 by using caulerpin and"/>
 <result pre="coronavirus pneumonia in Wuhan, China: a descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 6.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
</results>
